Consistently, this cluster also exhibited a higher percentage of IDH mutation, 1p/19q codeletion and MGMT-promoter methylation, which were all reported being associated with a favor prognosis in glioma (Hegi et al., 2005; Sabha et al., 2014). The gene discussed is IDH2; the disease is glioma.